Most common reasons for treatment discontinuations were bleeding complications (30% of all discontinuations), followed by other side-effects (24.2%) and diagnosis of stable sinus rhythm (9.9%).
The main reason for discontinuation is irregular bleeding.
Major bleeding necessitating discontinuation was seen in four patients (7%) whereas the other 21 patients (36.9%) died before completing 96 hours of therapy.
As a result, patients are put at increased risk for thromboembolism, bleeding, and premature discontinuation of anticoagulation therapy.
Twelve hours after discontinuation of aprotinin, fresh pulmonary bleeding again became apparent, together with an increase in FiO2 requirements to 1.0.
If the mother has fissures or bleeding nipples, temporary discontinuation of breast-feeding may be recommended, although thermal treatment (pasteurization or microwaving) of expressed milk before feeding the infant may be a safe alternative.
The most common reasons were bleeding complications (67/223 discontinuations; 30.0%) followed by non-bleeding side-effects (54/223; 24.2%), stable sinus rhythm (19/223; 8.5%), and worsening of renal function (18/223; 8.1%).
Registry data suggest that rivaroxaban persistence was greater than VKA persistence, with few discontinuations due to thromboembolic complications, although bleeding was the most frequent reason for discontinuation [ 63].
The most common side effect that caused discontinuation within 1 year was irregular bleeding.
However, none of these superficial bleeding events led to discontinuation of the extracorporeal treatment.
